Age: 48.0
Sex: F
Vaccine: COVID19
Symptoms: Pain, Vaccination site erythema, Vaccination site mass, Vaccination site pruritus
Clinical narrative: Headache; Body ache; Cough; Diarrhea; Sore throat; Hard lump and redness at injection site, itchy injection site; Hard lump and redness at injection site, itchy injection site; Hard lump and redness at injection site, itchy injection site; Dose number: 3; This is a spontaneous report from a contactable reporter (consumer or other non-HCP). The reporter is the patient.   A 48-year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 19Dec2021 at 11:15 (Lot number: 33130BA) at the age of 48 years as dose 3 (booster), single for COVID-19 immunisation. Relevant medical history included: "Chronic pain" (unspecified if ongoing); "Anxiety" (unspecified if ongoing); "Depression" (unspecified if ongoing); "ADD" (unspecified if ongoing), notes: ADD/ADHD; "ADHD" (unspecified if ongoing), notes: ADD/ADHD; "Egg allergy" (unspecified if ongoing), notes: Known allergies: Eggs and "Fruit allergy" (unspecified if ongoing), notes: banana. Concomitant medication(s) included: ADDERALL XR; CYMBALTA; WELLBUTRIN; TYLENOL and CODEINE. Past drug history included: Levaquin, reaction(s): "Drug allergy", notes: Known allergies: Levaquin and Cymbalta, reaction(s): "Drug allergy", notes: Known allergies: Cymbalta (must be watched). Vaccination history included: Bnt162b2 (DOSE 2, SINGLE; Lot number: Unknown; Route of administration: unspecified; Anatomical site: left arm), administration date: 28Apr2021, when the patient was 47 years old, for COVID-19 immunisation, reactions: "No adverse reaction" and Bnt162b2 (DOSE 1, SINGLE; Lot number: ER8734; Route of administration: unspecified; Anatomical site: left arm), administration date: 07Apr2021, when the patient was 47 years old, for COVID-19 immunisation, reactions: "No adverse reaction".  The following information was reported: IMMUNISATION (non-serious) with onset 19Dec2021 at 11:15, outcome "unknown", described as "Dose number: 3"; HEADACHE (non-serious) with onset 20Dec2021, outcome "unknown", described as "Headache"; PAIN (non-serious) with onset 20Dec2021, outcome "unknown", described as "Body ache"; COUGH (non-serious) with onset 20Dec2021, outcome "unknown", described as "Cough"; DIARRHOEA (non-serious) with onset 20Dec2021, outcome "unknown", described as "Diarrhea"; OROPHARYNGEAL PAIN (non-serious) with onset 20Dec2021, outcome "unknown", described as "Sore throat"; VACCINATION SITE MASS (non-serious), VACCINATION SITE ERYTHEMA (non-serious), VACCINATION SITE PRURITUS (non-serious) all with onset 20Dec2021, outcome "unknown", and all described as "Hard lump and redness at injection site, itchy injection site". Therapeutic measures were not taken as a result of headache, pain, cough, diarrhoea, oropharyngeal pain, vaccination site mass, vaccination site erythema and vaccination site pruritus.  Additional information: The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care.